Blood Cancer Talks

In this episode, we dive into updates in Minimal Residual Disease (MRD) in multiple myeloma, along with the FDA ODAC meeting in April 2024 to decide on MRD as a surrogate endpoint for accelerated approval. Our guests are Dr. Benjamin Derman and Dr. Manni Mohyuddin. Here are the key papers we discussed:

1.      Recording of FDA ODAC meeting:
2.     EVIDENCE meta-analysis on individual-level and trial-level correlation between MRD and PFS/OS in multiple myeloma:
3.     Predictors of un-sustained MRD-negativity in multiple myeloma: 
a)     Secondary analysis of FORTE trial:
b)     Secondary analysis of GEM2012MENOS65 and GEM2014MAIN trials:
4.     Kinetics of MRD resurgence and subsequent relapse in multiple myeloma:
5.     MRD2STOP trial (MRD-guided maintenance discontinuation):
6.     MRD-guided maintenance discontinuation in myeloma (Secondary analysis of GEM2012MENOS65 trial):

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk